Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials - The Lancet Oncology
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer | NEJM
ROS1: ROS Proto-oncogene 1
More Choices to Treat Lung Cancer | Cancer Today
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma - ScienceDirect
ROS1 Mutation in Lung Cancer - What is ROS1 Mutation in Lung Cancer?
Agents Targeting ROS1 Gain Traction in NSCLC
Recent Advances in Targeting ROS1 in Lung Cancer - ScienceDirect
AEACaP and LuCE host webinar on “ROS-1 Lung Cancer Patients”
Type of ROS1 rearrangement in nonsmall cell lung cancer. Exons 32, 34... | Download Scientific Diagram
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1 | NEJM
What Is ROS1-Positive Lung Cancer? | Massive Bio
ROS1 - Wikipedia
![PDF] Zeroing in on ROS1 Rearrangements in Non–Small Cell Lung Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1833bc15a861f5f020a9b9b360aab6055f53bdd6/2-Figure1-1.png "PDF] Zeroing in on ROS1 Rearrangements in Non–Small Cell Lung Cancer | Semantic Scholar")
PDF] Zeroing in on ROS1 Rearrangements in Non–Small Cell Lung Cancer | Semantic Scholar
GRACEcast-141_Lung_Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 - YouTube
Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer - ScienceDirect
ROS1-dependent cancers — biology, diagnostics and therapeutics | Nature Reviews Clinical Oncology
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers - ScienceDirect
Detection of ROS1 rearrangement in non-small cell lung cancer: current | LCTT
Cancers | Free Full-Text | N′1,N′3-Dimethyl-N′1,N′3-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS)
ALK and ROS1 - Disease Drivers in Cancer | Cell Signaling Technology
ROS1 and Lung Cancer | American Lung Association
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial - The Lancet Oncology
